TEANECK, N.J., Jan. 25, 2024 /PRNewswire/ -- Cognizant (NASDAQ: CTSH) announced today an expanded agreement with Takeda (NYSE: TAK), a global biopharmaceutical company, to support the company's digital transformation strategy by reinforcing and supporting its technology efforts. Together, Takeda and Cognizant will embark on a new project to attract additional technology talent and help Takeda further expand its Innovation Capability Center operations.
"Cognizant's support has complemented our continuous innovation and digital growth," said Sanjay Patel, Takeda Global Head of DD&T Innovation Capability Solutions. "This continued relationship will enable Takeda to accelerate our digital transformation journey, modernize our operational model, and speed time to market."
Cognizant will help Takeda deliver digital capabilities as a service to the organization by identifying and hiring key talent to support the company's data, digital and technology ambitions. Supporting Takeda in not only transforming modern infrastructure and application management approaches, but also through a unique "build, operate, transform and transfer," or BOTT model, Cognizant will set up the team, initiate operations, automate functions, and transfer to Takeda.
"Cognizant's long-standing relationship with Takeda combined with our digital transformation expertise will ensure that we are able to support Takeda's aspiration to become one of the most trusted, science-driven, digital biopharmaceutical companies," said Surya Gummadi, Executive Vice President and President of Cognizant Americas. "We're excited to collaborate with Takeda to support digital engagement experiences through enhanced technology solutions."
About Cognizant
Cognizant (Nasdaq: CTSH) engineers modern businesses. We help our clients modernize technology, reimagine processes and transform experiences so they can stay ahead in our fast-changing world. Together, we're improving everyday life. See how at www.cognizant.com or @cognizant.
Cognizant Contacts:
U.S.: Jeff DeMarrais
jeff.demarrais@cognizant.com
Europe/APAC: Christina Schneider
christina.schneider@cognizant.com
India: Rashmi Vasisht
rashmi.vasisht@cognizant.com
| Last Trade: | US$15.27 |
| Daily Change: | -0.01 -0.07 |
| Daily Volume: | 1,628,018 |
| Market Cap: | US$48.410B |
January 30, 2025 January 29, 2025 | |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
